§212.100

(b) Distribution records. You must maintain distribution records for each PET drug product that include or refer to the following:

1. The name, address, and telephone number of the receiving facility that received each batch of a PET drug product;
2. The name and quantity of the PET drug product shipped;
3. The lot number, control number, or batch number for the PET drug product shipped; and
4. The date and time you shipped the PET drug product.

Subpart K—Complaint Handling

§212.100 What do I do if I receive a complaint about a PET drug product produced at my facility?

(a) Written complaint procedures. You must develop and follow written procedures for the receipt and handling of all complaints concerning the quality or purity of, or possible adverse reactions to, a PET drug product.

(b) Complaint review. The procedures must include review by a designated person of any complaint involving the possible failure of a PET drug product to meet any of its specifications and an investigation to determine the cause of the failure.

(c) Complaint records. A written record of each complaint must be maintained in a file designated for PET drug product complaints. The record must include the name and strength of the PET drug product, the lot number, the name of the complainant, the date the complaint was received, the nature of the complaint, and the response to the complaint. It must also include the findings of any investigation and followup.

(d) Returned products. A PET drug product that is returned because of a complaint or for any other reason may not be reprocessed and must be destroyed in accordance with applicable Federal and State law.

Subpart L—Records

§212.110 How must I maintain records of my production of PET drugs?

(a) Record availability. Records must be maintained at the PET drug production facility or another location that is reasonably accessible to responsible officials of the production facility and to employees of FDA designated to perform inspections.

(b) Record quality. All records, including those not stored at the inspected establishment, must be legible, stored to prevent deterioration or loss, and readily available for review and copying by FDA employees.

(c) Record retention period. You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.

PART 216—PHARMACY COMPOUNDING

Subpart A—General Provisions [Reserved]

Subpart B—Compounded Drug Products

Sec.

216.23 [Reserved]

216.24 Drug products withdrawn or removed from the market for reasons of safety or effectiveness.


SOURCE: 64 FR 10944, Mar. 8, 1999, unless otherwise noted.

Subpart A—General Provisions [Reserved]

Subpart B—Compounded Drug Products

§216.23 [Reserved]

§216.24 Drug products withdrawn or removed from the market for reasons of safety or effectiveness.

The following drug products were withdrawn or removed from the market because such drug products or components of such drug products were found to be unsafe or not effective. The following drug products may not be
compounded under the exemptions provided by section 503A(a) of the Federal Food, Drug, and Cosmetic Act:

**Adenosine phosphate:** All drug products containing adenosine phosphate.

**Adrenal cortex:** All drug products containing adrenal cortex.

**Azaribine:** All drug products containing azaribine.

**Benoxaprofen:** All drug products containing benoxaprofen.

**Bithionol:** All drug products containing bithionol.

**Bromfenac sodium:** All drug products containing bromfenac sodium.

**Bithionol:** All drug products containing bithionol.

**Camphorated oil:** All drug products containing camphorated oil.

**Carbetapentane citrate:** All oral gel drug products containing carbetapentane citrate.

**Casein, iodinated:** All drug products containing iodinated casein.

**Chlorhexidine gluconate:** All tinctures of chlorhexidine gluconate formulated for use as a patient preoperative skin preparation.

**Chlorormadinone acetate:** All drug products containing chlorormadinone acetate.

**Chloroform:** All drug products containing chloroform.

**Cobalt:** All drug products containing cobalt salts and cobalamin and its derivatives.

**Dexfenfluramine hydrochloride:** All drug products containing dexfenfluramine hydrochloride.

**Diamthazole dihydrochloride:** All drug products containing diamthazole dihydrochloride.

**Dibromsalan:** All drug products containing dibromsalan.

**Diethylstilbestrol:** All oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.

**Dihydrostreptomycin sulfate:** All drug products containing dihydrostreptomycin sulfate.

**Dipyrene:** All drug products containing dipyrene.

**Encainide hydrochloride:** All drug products containing encainide hydrochloride.

**Fenfluramine hydrochloride:** All drug products containing fenfluramine hydrochloride.

**Flosequinan:** All drug products containing flosequinan.

**Gelatin:** All intravenous drug products containing gelatin.

**Glycerol, iodinated:** All drug products containing iodinated glycerol.

**Gonadotropin, chorionic:** All drug products containing chorionic gonadotropins of animal origin.

**Mepazine:** All drug products containing mepazine hydrochloride or mepazine acetate.

**Metabolism:** All drug products containing metabolism.

**Methamphetamine hydrochloride:** All parenteral drug products containing methamphetamine hydrochloride.

**Methapyrilene:** All drug products containing methapyrilene.

**Methamphetamine:** All drug products containing methamphetamine.

**Mibefradil dihydrochloride:** All drug products containing mibefradil dihydrochloride.

**Nitrofurazone:** All drug products containing nitrofurazone (except topical drug products formulated for dermatologic application).

**Nomifensine maleate:** All drug products containing nomifensine maleate.

**Oxyphenisatin:** All drug products containing oxyphenisatin.

**Oxyphenisatin acetate:** All drug products containing oxyphenisatin acetate.

**Pheacetin:** All drug products containing pheacetin.

**Phenformin hydrochloride:** All drug products containing phenformin hydrochloride.

**Pipamazine:** All drug products containing pipamazine.

**Potassium arsenite:** All drug products containing potassium arsenite.

**Potassium chloride:** All solid oral dosage form drug products containing potassium chloride that supply 100 milligrams or more of potassium per dosage unit (except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion).

**Povidone:** All intravenous drug products containing povidone.

**Reserpine:** All oral dosage form drug products containing more than 1 milligram of reserpine.

**Sparteine sulfate:** All drug products containing sparteine sulfate.

**Sulfonamide:** All drug products containing sulfonamide (except those formulated for vaginal use).

**Suprofen:** All drug products containing suprofen (except ophthalmic solutions).

**Sweet spirits of nitre:** All drug products containing sweet spirits of nitre.

**Temafloxacin hydrochloride:** All drug products containing temafloxacin.

**Terfenadine:** All drug products containing terfenadine.

**Tribromsalan:** All drug products containing tribromsalan.
Trichloroethane: All aerosol drug products intended for inhalation containing trichloroethane.

Urethane: All drug products containing urethane.

Vinyl chloride: All aerosol drug products containing vinyl chloride.

Zirconium: All aerosol drug products containing zirconium.

Zomepirac sodium: All drug products containing zomepirac sodium.

PART 225—CURRENT GOOD MANUFACTURING PRACTICE FOR MEDICATED FEEDS

Subpart A—General Provisions

Sec.
225.1 Current good manufacturing practice.
225.10 Personnel.

Subpart B—Construction and Maintenance of Facilities and Equipment

225.20 Buildings.
225.30 Equipment.
225.35 Use of work areas, equipment, and storage areas for other manufacturing and storage purpose.

Subpart C—Product Quality Control

225.42 Components.
225.58 Laboratory controls.
225.65 Equipment cleanout procedures.

Subpart D—Packaging and Labeling

225.80 Labeling.

Subpart E—Records and Reports

225.102 Master record file and production records.
225.110 Distribution records.
225.115 Complaint files.

Subpart F—Facilities and Equipment

225.120 Buildings and grounds.
225.130 Equipment.
225.135 Work and storage areas.

Subpart G—Product Quality Assurance

225.142 Components.
225.158 Laboratory assays.
225.165 Equipment cleanout procedures.

Subpart H—Labeling

225.180 Labeling.

Subpart I—Records

225.202 Formula, production, and distribution records.